Developer docs
API playgroundTry for free, no card

Search company profiles

Nintx

Full company profile

uuid00023n8

Namestring
Nintx
Legal namestring
Nintx
Websiteurl
nintx.com.br
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Nintx (Next Innovative Therapeutics) is a Brazilian biotech startup founded in 2021 that develops multi-target therapies leveraging the country's biodiversity and the human gut microbiome. The company's scientific premise is that most major diseases (cancer, neurodegenerative, cardiometabolic, immunological, and inflammatory bowel diseases) are multifactorial and linked to complex interactions between genetic, environmental, and microbiome factors, and that plant-based natural products can modulate human targets both directly and indirectly via interspecies molecular crosstalk with gut microorganisms.

Nintx operates two proprietary technology platforms: GAIApath, a data analytics knowledge graph used to map and select medicinal plants from Brazilian biodiversity capable of modulating targets and the gut microbiome concomitantly; and xGIbiomics, an in vitro platform that emulates the human gastrointestinal digestive system (controlling pH, volume, agitation, flow rate, temperature, enzymes, microorganisms, anaerobiosis, O2 levels, and metabolites) to study short- and long-term gut microbiome modulation. The pipeline includes seven pharmaceutical programs (NTX-03 cardiometabolic, NTX-04 IBS, NTX-05 immuno-oncology, NTX-06 IBD, NTX-10 Alzheimer's, NTX-11 metabolic syndrome, NTX-12 psoriasis) and ten nutraceutical products (PBTX-01 through PBTX-12) covering newborn GI health, gluten sensitivity, digestive support, gut-barrier restoration, gut-brain and gut-skin axis modulation, immune health, circadian rhythm, and mitochondrial metabolism.

The business model is B2B, combining three revenue streams: pharmaceutical licensing and co-development with major pharma (planned within five years), contract microbiome research services for food and nutrition companies (e.g., Lactalis), and nutraceutical product launches through partner laboratories. The company is pre-revenue, headquartered in São Paulo with an R&D lab in Campinas (the first private human intestinal microbiome laboratory in Latin America), and has raised approximately US$16 million across a US$3M seed (2022), a US$10M Series A (2024), and ~US$3M in grants from FINEP and PIPE/Fapesp.

Short descriptiontext

Nintx is a Brazilian biotech startup that uses proprietary GAIApath and xGIbiomics platforms to develop multi-target plant-based therapies modulating human biology via the gut microbiome. It serves pharmaceutical, food/nutrition, and nutraceutical markets through licensing, contract research, and consumer health products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSão Paulo, Brazil
HQ citystring
São Paulo
HQ countrystring
Brazil
HQ regionstring
Latin America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery platform, microbiome research services, natural product therapeutics, multi-target therapies, biotech pharmaceutical
Industry2 codes
PRIMARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Biotechnology Drug Discovery
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Licensing and Co-development
TypeLicensing Royalties
Description

Plans to commercialize technology to major pharmaceutical companies within five years through licensing deals and co-development partnerships for drug programs targeting multifactorial diseases.

nintx.com.br
2Nutraceutical Product Development
TypeOne Time License
Description

Development and launch of nutraceutical products including formulas for gluten-intolerant patients, digestive support, microbiome modulation, and other health applications. First launch planned through partner laboratory.

nintx.com.br
3Contract Research Services
TypeProfessional Services
Description

Provides gut microbiome research services to food and nutrition companies using proprietary xGIbiomics technology, such as the Lactalis collaboration for prebiotic ingredient validation.

nintx.com.br
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1GAIApath®
Description

Nintx's proprietary data analytics knowledge graph infrastructure to map and select medicinal plants from nature's biodiversity with the ability to modulate targets and the gut microbiome concomitantly.

nintx.com.br
+1 more record
Core offering1 text field

Nintx develops a new generation of medicines by leveraging Brazilian biodiversity and gut microbiome science. Its core consists of two proprietary platforms—GAIApath® (a knowledge graph for selecting medicinal plants) and xGIbiomics® (an in vitro gut microbiome simulator)—used to discover and develop multi-target pharmaceutical programs (NTX series) and nutraceutical products (PBTX series). The company offers contract gut microbiome research services to food and nutrition companies and plans to license and co-develop its drug pipeline with major pharmaceutical companies within five years.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Lactose demonstrated as viable prebiotic alternative to inulin in synbiotic formulations, promoting enhanced production of short-chain fatty acids and growth of beneficial bacteria (Lactobacillus and Bifidobacterium)
+1 more record
Product overview1 text field

Nintx (Next Innovative Therapeutics) is a biotech company founded in Brazil in 2021 that develops multi-target therapies based on Brazilian biodiversity, focusing on plant-based natural products to modulate human biological targets directly and indirectly via the gut microbiome. The company's core offerings consist of two proprietary technology platforms: GAIApath® (data analytics knowledge graph for medicinal plant selection) and xGIbiomics® (in vitro gut microbiome simulation technology). Nintx's product portfolio includes a pharmaceutical pipeline with 7 drug programs (NTX-03, NTX-04, NTX-05, NTX-06, NTX-10, NTX-11, NTX-12) targeting cardiometabolic, gastroenterology, immunology, neuroscience, and dermatology conditions, and a nutraceutical pipeline with 10 products (PBTX-01 through PBTX-12) addressing gut health, microbiome modulation, immune support, and metabolic functions. The company operates in both pharmaceutical and nutraceutical markets, with plans to commercialize technology to major pharmaceutical companies within five years.

Product and service3 records
1xGIbiomics® Gut Microbiome Research Services
CategoryContract research services
Description

Contract gut microbiome research services delivered using Nintx's proprietary xGIbiomics in vitro platform, which emulates the human gastrointestinal digestive system (pH, volume, agitation, flow rate, temperature, enzymes, microorganisms, anaerobiosis, O2 level, metabolites). Services are offered to food, dairy, and nutrition companies for prebiotic and synbiotic ingredient validation, functional food development, and gut health research.

2PBTX Nutraceutical Product Line
CategoryNutraceutical products
Description

A planned portfolio of 12 plant-based, microbiome-modulating nutraceutical products (PBTX-01 through PBTX-12) addressing newborn gastrointestinal health, non-celiac gluten sensitivity, broad-spectrum digestive support, irritable bowel syndrome, gut-barrier restoration, gut-brain axis modulation, gut-skin axis modulation, immune health, circadian cycle modulation, and mitochondrial metabolism. First product (PBTX-02) is being launched through a partner laboratory in Brazil.

3NTX Multi-Target Therapy Co-Development Programs
CategoryPharmaceutical R&D programs
Description

Pre-clinical multi-target drug programs (NTX-03 cardiometabolic/liver-cardiac regeneration, NTX-04 IBS, NTX-05 immuno-oncology, NTX-06 inflammatory bowel disease, NTX-10 Alzheimer's, NTX-11 metabolic syndrome, NTX-12 psoriasis) developed for licensing and co-development with major pharmaceutical companies within five years. First program is the Centroflora-partnered Amazon-sourced multi-target therapy for an undisclosed therapeutic area.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1CIEnP (Center for Innovation and Pre-Clinical Trials)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-15
Description

Partnership for pre-clinical development of multi-target therapy with global reach for inflammatory bowel disease based on Brazilian biodiversity. Project won FINEP Innovation Award 2025.

nintx.com.br
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-10
Description

Co-development partnership to create innovative multi-target therapy using Amazon rainforest herbaceous plant. Centroflora provides cultivation and extraction expertise; Nintx provides discovery and development capabilities.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Provides support for the multi-target therapy project with expertise and resources for innovation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

World's largest dairy company engaged Nintx for gut microbiome research using xGIbiomics technology to explore lactose as a prebiotic ingredient. Resulted in published scientific article.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Invited Nintx CEO to participate in COP30 panel on 'Multiple Perspectives of Science and Technology in Favor of Amazonian Sociobiodiversity'. Partnership toward regenerative bioeconomy.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Brazilian pharmaceutical association that organized Brazilian Pavillion, 4th Brazilian Startup Day, and BiodiversiTx session at BIO International Convention where Nintx conducted strategic meetings.

7Sindusfarma, RBIF, Biominas Brasil
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Organizers of IV Brazilian Health Innovation Summit where CEO Stephani Saverio participated in panel on Intestinal Microbiota.

nintx.com.br
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing defined bacterial consortia for immune-mediated diseases. Directly comparable to Nintx as a microbiome-modulating drug discovery platform pursuing pharma partnerships and licensing economics.

TypeBroad incumbent
Description

Pioneer microbiome therapeutics company with SER-109 (VOWST) approved for recurrent C. difficile. Comparable as a leading microbiome-based drug developer targeting multifactorial indications via gut microbiome modulation.

34D pharma
TypeDirect peer
Description

UK-based microbiome therapeutics company developing single-strain live biotherapeutics for cancer, respiratory, and gastrointestinal indications. Comparable to Nintx in pursuing microbiome-based multi-target therapies and pharma licensing.

TypeDirect peer
Description

US-based biotech harnessing interactions between plants and microorganisms to develop microbiome-modulating therapeutics. Closely aligned with Nintx's plant-microbiome interspecies approach and similar drug-discovery positioning.

5Second Genome
TypeDirect peer
Description

Microbiome drug discovery platform identifying microbiome-derived targets and therapeutics. Comparable to Nintx as a platform biotech leveraging microbiome science to develop novel drug candidates for partner pharma companies.

TypeEmerging player
Description

Clinical-stage microbiome company developing phage-based and engineered bacterial therapeutics. Comparable emerging player in the microbiome therapeutics category with similar small-cap, early-stage profile.

7Kaleido Biosciences
TypeEmerging player
Description

Previously public microbiome therapeutics company developing novel chemistries to modulate the gut microbiome. Comparable in therapeutic strategy and platform approach, though broader in indication scope.

8Eurofarma
TypeBroad incumbent
Description

Largest Brazilian-owned pharmaceutical company with diversified branded generics and innovation pipeline. Comparable as the most relevant Brazilian pharma incumbent that Nintx may seek as a domestic licensing or co-development partner.

TypeBroad incumbent
Description

Major Brazilian pharmaceutical company with established branded generics, oncology, and innovation initiatives. Comparable regional incumbent that could serve as a Brazilian pharma licensing counterparty for Nintx's pipeline.

10Diversigen (Eurofins Genomics)
TypeOthers
Description

Provider of microbiome sequencing, bioinformatics, and analytics services for pharma and academic clients. Comparable as an enabler/ecosystem participant whose services overlap with Nintx's xGIbiomics capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nintx

Biotechnology Drug Discoverynintx.com.br

Nintx is a Brazilian biotech startup that uses proprietary GAIApath and xGIbiomics platforms to develop multi-target plant-based therapies modulating human biology via the gut microbiome. It serves pharmaceutical, food/nutrition, and nutraceutical markets through licensing, contract research, and consumer health products.

What Nintx does

Nintx (Next Innovative Therapeutics) is a Brazilian biotech startup founded in 2021 that develops multi-target therapies leveraging the country's biodiversity and the human gut microbiome. The company's scientific premise is that most major diseases (cancer, neurodegenerative, cardiometabolic, immunological, and inflammatory bowel diseases) are multifactorial and linked to complex interactions between genetic, environmental, and microbiome factors, and that plant-based natural products can modulate human targets both directly and indirectly via interspecies molecular crosstalk with gut microorganisms.

Nintx operates two proprietary technology platforms: GAIApath, a data analytics knowledge graph used to map and select medicinal plants from Brazilian biodiversity capable of modulating targets and the gut microbiome concomitantly; and xGIbiomics, an in vitro platform that emulates the human gastrointestinal digestive system (controlling pH, volume, agitation, flow rate, temperature, enzymes, microorganisms, anaerobiosis, O2 levels, and metabolites) to study short- and long-term gut microbiome modulation. The pipeline includes seven pharmaceutical programs (NTX-03 cardiometabolic, NTX-04 IBS, NTX-05 immuno-oncology, NTX-06 IBD, NTX-10 Alzheimer's, NTX-11 metabolic syndrome, NTX-12 psoriasis) and ten nutraceutical products (PBTX-01 through PBTX-12) covering newborn GI health, gluten sensitivity, digestive support, gut-barrier restoration, gut-brain and gut-skin axis modulation, immune health, circadian rhythm, and mitochondrial metabolism.

The business model is B2B, combining three revenue streams: pharmaceutical licensing and co-development with major pharma (planned within five years), contract microbiome research services for food and nutrition companies (e.g., Lactalis), and nutraceutical product launches through partner laboratories. The company is pre-revenue, headquartered in São Paulo with an R&D lab in Campinas (the first private human intestinal microbiome laboratory in Latin America), and has raised approximately US$16 million across a US$3M seed (2022), a US$10M Series A (2024), and ~US$3M in grants from FINEP and PIPE/Fapesp.

Nintx firmographics

Firmographics
Name
Nintx
Legal name
Nintx
Website
https://nintx.com.br
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Nintx is a Brazilian biotech startup that uses proprietary GAIApath and xGIbiomics platforms to develop multi-target plant-based therapies modulating human biology via the gut microbiome. It serves pharmaceutical, food/nutrition, and nutraceutical markets through licensing, contract research, and consumer health products.
Ownership category
akta.pro rank

Nintx industry classification

Industry
Product category
Biotechnology Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGANAH
Microbiome & Metagenomics Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Drug discovery platform
  • Microbiome research services
  • Natural product therapeutics
  • Multi-target therapies
  • Biotech pharmaceutical

Where Nintx is headquartered

Location

Headquarters

HQ city
São Paulo
HQ country
Brazil
HQ region
Latin America

Offices2 records

Markets served

Nintx business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Licensing and Co-development: Plans to commercialize technology to major pharmaceutical companies within five years through licensing deals and co-development partnerships for drug programs targeting multifactorial diseases.
  2. Nutraceutical Product Development: Development and launch of nutraceutical products including formulas for gluten-intolerant patients, digestive support, microbiome modulation, and other health applications. First launch planned through partner laboratory.
  3. Contract Research Services: Provides gut microbiome research services to food and nutrition companies using proprietary xGIbiomics technology, such as the Lactalis collaboration for prebiotic ingredient validation.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Nintx product offering

Product offering

Core offering

Nintx develops a new generation of medicines by leveraging Brazilian biodiversity and gut microbiome science. Its core consists of two proprietary platforms—GAIApath® (a knowledge graph for selecting medicinal plants) and xGIbiomics® (an in vitro gut microbiome simulator)—used to discover and develop multi-target pharmaceutical programs (NTX series) and nutraceutical products (PBTX series). The company offers contract gut microbiome research services to food and nutrition companies and plans to license and co-develop its drug pipeline with major pharmaceutical companies within five years.

Product overview

Nintx (Next Innovative Therapeutics) is a biotech company founded in Brazil in 2021 that develops multi-target therapies based on Brazilian biodiversity, focusing on plant-based natural products to modulate human biological targets directly and indirectly via the gut microbiome. The company's core offerings consist of two proprietary technology platforms: GAIApath® (data analytics knowledge graph for medicinal plant selection) and xGIbiomics® (in vitro gut microbiome simulation technology). Nintx's product portfolio includes a pharmaceutical pipeline with 7 drug programs (NTX-03, NTX-04, NTX-05, NTX-06, NTX-10, NTX-11, NTX-12) targeting cardiometabolic, gastroenterology, immunology, neuroscience, and dermatology conditions, and a nutraceutical pipeline with 10 products (PBTX-01 through PBTX-12) addressing gut health, microbiome modulation, immune support, and metabolic functions. The company operates in both pharmaceutical and nutraceutical markets, with plans to commercialize technology to major pharmaceutical companies within five years.

Differentiator

Problem solved

Functional benefit

Brands

  • GAIApath®: Nintx's proprietary data analytics knowledge graph infrastructure to map and select medicinal plants from nature's biodiversity with the ability to modulate targets and the gut microbiome concomitantly.
  • xGIbiomics®

Products and services

  • xGIbiomics® Gut Microbiome Research Services Contract gut microbiome research services delivered using Nintx's proprietary xGIbiomics in vitro platform, which emulates the human gastrointestinal digestive system (pH, volume, agitation, flow rate, temperature, enzymes, microorganisms, anaerobiosis, O2 level, metabolites). Services are offered to food, dairy, and nutrition companies for prebiotic and synbiotic ingredient validation, functional food development, and gut health research.
  • PBTX Nutraceutical Product Line A planned portfolio of 12 plant-based, microbiome-modulating nutraceutical products (PBTX-01 through PBTX-12) addressing newborn gastrointestinal health, non-celiac gluten sensitivity, broad-spectrum digestive support, irritable bowel syndrome, gut-barrier restoration, gut-brain axis modulation, gut-skin axis modulation, immune health, circadian cycle modulation, and mitochondrial metabolism. First product (PBTX-02) is being launched through a partner laboratory in Brazil.
  • NTX Multi-Target Therapy Co-Development Programs Pre-clinical multi-target drug programs (NTX-03 cardiometabolic/liver-cardiac regeneration, NTX-04 IBS, NTX-05 immuno-oncology, NTX-06 inflammatory bowel disease, NTX-10 Alzheimer's, NTX-11 metabolic syndrome, NTX-12 psoriasis) developed for licensing and co-development with major pharmaceutical companies within five years. First program is the Centroflora-partnered Amazon-sourced multi-target therapy for an undisclosed therapeutic area.

Quantifiable outcome

  • Lactose demonstrated as viable prebiotic alternative to inulin in synbiotic formulations, promoting enhanced production of short-chain fatty acids and growth of beneficial bacteria (Lactobacillus and Bifidobacterium)
  • +1 more outcomes

Companies that use Nintx

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Nintx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Nintx partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • CIEnP (Center for Innovation and Pre-Clinical Trials)coreStrategic or Co-development Partner · 15 August 2024Partnership for pre-clinical development of multi-target therapy with global reach for inflammatory bowel disease based on Brazilian biodiversity. Project won FINEP Innovation Award 2025.
  • Grupo CentrofloracoreStrategic or Co-development Partner · 10 January 2023Co-development partnership to create innovative multi-target therapy using Amazon rainforest herbaceous plant. Centroflora provides cultivation and extraction expertise; Nintx provides discovery and development capabilities.
  • Embrapii (Brazilian Company of Industrial Research and Innovation)minorStrategic or Co-development PartnerProvides support for the multi-target therapy project with expertise and resources for innovation.
  • Grupo LactalisminorStrategic or Co-development PartnerWorld's largest dairy company engaged Nintx for gut microbiome research using xGIbiomics technology to explore lactose as a prebiotic ingredient. Resulted in published scientific article.
  • NaturaminorStrategic or Co-development PartnerInvited Nintx CEO to participate in COP30 panel on 'Multiple Perspectives of Science and Technology in Favor of Amazonian Sociobiodiversity'. Partnership toward regenerative bioeconomy.
  • ABIQUIFIminorStrategic or Co-development PartnerBrazilian pharmaceutical association that organized Brazilian Pavillion, 4th Brazilian Startup Day, and BiodiversiTx session at BIO International Convention where Nintx conducted strategic meetings.
  • Sindusfarma, RBIF, Biominas BrasilminorStrategic or Co-development PartnerOrganizers of IV Brazilian Health Innovation Summit where CEO Stephani Saverio participated in panel on Intestinal Microbiota.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Nintx competitors and assessment

Company assessment

Direct peers

  • Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined bacterial consortia for immune-mediated diseases. Directly comparable to Nintx as a microbiome-modulating drug discovery platform pursuing pharma partnerships and licensing economics.
  • 4D pharma: UK-based microbiome therapeutics company developing single-strain live biotherapeutics for cancer, respiratory, and gastrointestinal indications. Comparable to Nintx in pursuing microbiome-based multi-target therapies and pharma licensing.
  • Solarea Bio: US-based biotech harnessing interactions between plants and microorganisms to develop microbiome-modulating therapeutics. Closely aligned with Nintx's plant-microbiome interspecies approach and similar drug-discovery positioning.
  • Second Genome: Microbiome drug discovery platform identifying microbiome-derived targets and therapeutics. Comparable to Nintx as a platform biotech leveraging microbiome science to develop novel drug candidates for partner pharma companies.

Broad incumbents

  • Seres Therapeutics: Pioneer microbiome therapeutics company with SER-109 (VOWST) approved for recurrent C. difficile. Comparable as a leading microbiome-based drug developer targeting multifactorial indications via gut microbiome modulation.
  • Eurofarma: Largest Brazilian-owned pharmaceutical company with diversified branded generics and innovation pipeline. Comparable as the most relevant Brazilian pharma incumbent that Nintx may seek as a domestic licensing or co-development partner.
  • Aché Laboratórios: Major Brazilian pharmaceutical company with established branded generics, oncology, and innovation initiatives. Comparable regional incumbent that could serve as a Brazilian pharma licensing counterparty for Nintx's pipeline.

Emerging players

  • BiomX: Clinical-stage microbiome company developing phage-based and engineered bacterial therapeutics. Comparable emerging player in the microbiome therapeutics category with similar small-cap, early-stage profile.
  • Kaleido Biosciences: Previously public microbiome therapeutics company developing novel chemistries to modulate the gut microbiome. Comparable in therapeutic strategy and platform approach, though broader in indication scope.

Others

  • Diversigen (Eurofins Genomics): Provider of microbiome sequencing, bioinformatics, and analytics services for pharma and academic clients. Comparable as an enabler/ecosystem participant whose services overlap with Nintx's xGIbiomics capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Nintx social profiles

Digital presence

Nintx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nintx leadership team

Management profile

Number of profiles

Profiles10 records

Nintx funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nintx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nintx

What does Nintx do?

Nintx develops a new generation of medicines by leveraging Brazilian biodiversity and gut microbiome science. Its core consists of two proprietary platforms—GAIApath® (a knowledge graph for selecting medicinal plants) and xGIbiomics® (an in vitro gut microbiome simulator)—used to discover and develop multi-target pharmaceutical programs (NTX series) and nutraceutical products (PBTX series). The company offers contract gut microbiome research services to food and nutrition companies and plans to license and co-develop its drug pipeline with major pharmaceutical companies within five years.

Is Nintx a public or private company?

Nintx is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nintx founded?

Nintx was founded in 2021. It employs 11 to 50 people.

Where is Nintx based?

Nintx is headquartered in São Paulo, Brazil, in the Latin America region.

How does Nintx make money?

Three revenue lines are on record. Pharmaceutical Licensing and Co-development is the primary driver. The others are nutraceutical Product Development and contract Research Services.

Who are Nintx's main competitors?

Direct peers on record are Vedanta Biosciences, 4D pharma, Solarea Bio and Second Genome. Broad incumbents are Seres Therapeutics, Eurofarma and Aché Laboratórios. Emerging players are BiomX and Kaleido Biosciences. Diversigen (Eurofins Genomics) is listed as an others.

Does Nintx have an API?

No public API is recorded for Nintx.

What industry is Nintx in?

Nintx's product category is Biotechnology Drug Discovery. Its primary akta.pro industry code is HLAAAFAI, Microbiome Analytics, Sequencing & Bioinformatics Platforms, with a secondary code of HLAGANAH, Microbiome & Metagenomics Services. Its NAICS code is 541714 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pegnNintx taps Brazil’s biodiversity for innovative medicinesNintx, a Brazilian biotech startup, received a $10 million investment in December and tripled its laboratory size in Campinas. The company aims to develop drugs for neurological diseases and nutraceuticals, with two product launches planned between 2025 and 2026.StartupiAdeste participa de investimento de US$ 10 milhões na NintxAdeste, a health and animal nutrition company, invested $10 million in Nintx, a Brazilian biotech developing medicines from Brazilian biodiversity. The investment, from investors including Fundo Pitanga and Guilherme Leal, aims to accelerate Nintx's research on multi-target drugs. Adeste's CEO said the partnership supports innovation and long-term strategic alliances.FinSMEsNintx Raises US$10M in FundingNintx, a São Paulo-based biotech, raised US$10M in Series A funding from Pitanga, Ecoa Capital, and MOV Investimentos, with a US$2.5M FINEP grant. The funds will support R&D of eight new drug programs, hiring, and laboratory expansion. The company targets multifactorial diseases via gut microbiome modulation.Business Wire BlogBiotech Nintx Raises US$ 10 Million to Advance a New Generation of Medicines Based on Brazilian BiodiversityNintx, a Brazilian biotech, raised US$10 million in a Series A round led by Pitanga, Ecoa Capital, and MOV Investimentos, plus a US$2.5 million grant from FINEP. The funds will accelerate R&D of eight drug programs, with the first candidate expected to be licensed within three years.Business Wire BlogBiotech Nintx Raises US$ 10 Million to Advance a New Generation of Medicines Based on Brazilian BiodiversityNintx, a Brazilian biotech, raised US$10 million in a Series A round led by Pitanga, Ecoa Capital, and MOV Investimentos, plus a US$2.5 million FINEP grant. The funds will support R&D of eight drug programs, hiring, and lab expansion, with the first drug candidate expected to be licensed within three years.